Business Context and Reporting Period
Puma Biotechnology, Inc. (PBYI) filed this Form 8-K on June 28, 2019, to disclose the entry into a material definitive agreement regarding its debt structure. The company is a Delaware corporation with principal executive offices in Los Angeles, California.
Key Financial Metrics and Debt Structure
The filing details a refinancing transaction executed on June 28, 2019:
- Debt Repayment: The company repaid $155.0 million outstanding under its prior credit facility, including applicable exit and prepayment fees.
- New Borrowings: The company entered into an amended and restated loan and security agreement (the "new credit facility") with Oxford Finance LLC and other lenders, borrowing $100.0 million.
- Funding Source: The repayment of the prior facility was funded using cash on hand and the $100.0 million in new borrowings.
- Interest Rate: Term loans bear interest at the greater of 9.0% or the prime rate plus 3.5%.
- Collateral: The facility is secured by substantially all personal property (excluding intellectual property) and 65% of the capital stock of subsidiaries Puma Biotechnology Ltd. and Puma Biotechnology B.V.
- Final Payment: Upon repayment, the company must make a final payment equal to 7.5% of the aggregate principal amount outstanding as of the Effective Date.
Material Changes Versus Prior Period
The primary material change is the restructuring of the company's credit facility. The prior facility was fully extinguished and replaced with a new facility that has different terms, including a maturity date of June 1, 2024, and specific revenue covenants. No additional money remains available under the new facility.
Guidance, Covenants, and Risks
Repayment Terms: Monthly interest-only payments are required until August 1, 2021 (Amortization Date). Principal and interest payments commence thereafter, with full maturity on June 1, 2024.
Prepayment Penalties: Prepayment is permitted in whole but not in part, subject to fees of 3.0% (first anniversary), 2.0% (second anniversary), or 1.0% (after second anniversary).
Covenants:
- Affirmative: Includes maintaining legal existence, delivering financial reports, and achieving specific product revenue levels on a trailing year-to-date basis for quarters ending June 30, September 30, and December 31, 2019.
- Negative: Restrictions on incurring additional indebtedness, mergers, acquisitions, dividends, asset sales, and changes in control.
Risks and Events of Default: Default events include failure to pay, covenant breaches, insolvency, material adverse changes, or judgments exceeding $500,000. Default triggers a 5.0% penalty interest rate and allows lenders to exercise remedies, including foreclosure on collateral and cash.
Investor Verification Checklist
- Verify the company's ability to meet the specific product revenue covenants for the quarters ending June 30, September 30, and December 31, 2019.
- Confirm the company's cash position to ensure it can service the monthly interest-only payments and the 7.5% final payment obligation.
- Review the upcoming Form 10-Q for the quarter ended June 30, 2019, which will contain the full text of the new credit facility and promissory notes.
- Monitor for any material adverse changes or judgments exceeding $500,000 that could trigger an event of default.